Asset Details
Do you wish to reserve the book?
Macrophage activation marker sCD163 is associated with liver injury and hepatic insulin resistance in obese patients before and after Roux‐en‐Y gastric bypass
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Macrophage activation marker sCD163 is associated with liver injury and hepatic insulin resistance in obese patients before and after Roux‐en‐Y gastric bypass
Do you wish to request the book?
Macrophage activation marker sCD163 is associated with liver injury and hepatic insulin resistance in obese patients before and after Roux‐en‐Y gastric bypass
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Macrophage activation marker sCD163 is associated with liver injury and hepatic insulin resistance in obese patients before and after Roux‐en‐Y gastric bypass
2022
Overview
Background Macrophages are associated with metabolic complications to obesity including fatty liver disease and impaired hepatic and muscle insulin sensitivity (IS). Bariatric surgery induces weight loss and improves IS. We investigated associations between the macrophage activation marker soluble (s)CD163, alanine‐aminotransferase (ALT), and IS before and after Roux‐en‐Y Gastric Bypass (RYGB). Methods We analyzed sCD163 from 10 type 2 diabetes (T2D) and 10 obese patients with normal glucose tolerance (NGT) undergoing RYGB for associations with hepatic, adipose tissue, and muscle IS and ALT after 1‐week, 3, and 12 months postoperatively. IS was evaluated by hyperinsulinemic‐euglycemic clamp in combination with glucose tracer technique. Results Preoperative sCD163 correlated with ALT (r = 0.58, p = 0.007) and tended to associate inversely with hepatic (r = −0.39, p = 0.1) and adipose tissue (r = −0.39, p = 0.09), but not muscle IS. Following RYGB, sCD163 decreased significantly in all patients. The decrease in sCD163 during the first 3 months correlated inversely with the improvement of hepatic IS (r = −0.65, p = 0.01) and tended to be associated with changes in muscle IS (r = −0.45, p = 0.09). After 3 months sCD163 remained associated with ALT (r = 0.75, p < 0.001) and inversely with hepatic IS (r = −0.39, p = 0.1), but not muscle or adipose tissue IS. One year after RYGB, sCD163 correlated with ALT (r = 0.61, p = 0.007), but not with hepatic, adipose tissue, or muscle IS. Conclusion Macrophage activation is associated with liver injury and hepatic IS in obese patients. Improvements in these measures correlate during the first 3 months following RYGB, supporting a link between macrophages and hepatic IS in severe obesity and diabetes. Macrophage activation assessed by soluble CD163 is associated with hepatic insulin resistance in patients with severe obesity and its improvement after Roux‐en‐Y gastric bypass and weight loss.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
Subject
/ Alanine
/ Body fat
/ Diabetes
/ Diabetes mellitus (non-insulin dependent)
/ Diabetes Mellitus, Type 2 - complications
/ Diabetes Mellitus, Type 2 - metabolism
/ Diabetes Mellitus, Type 2 - surgery
/ Gastric Bypass - adverse effects
/ Glucose
/ Humans
/ Insulin
/ Insulin Resistance - physiology
/ Liver
/ Obesity
/ Original
/ Patients
/ Peptides
/ Plasma
